GlycoMimetics Inc (CBIO) Stock Forecast & Price Target

Crescent Biopharma is viewed positively because CR-001 is backed by strong class validation from ivonescimab, whose Phase 3 HARMONi-2 data showed a 27% mortality risk reduction versus pembrolizumab, median OS of 30.8 versus 22.6 months, and manageable safety. The company also has multiple shots on goal: ASCEND has completed dose escalation, enrolled >125 patients, and opened chemo-combo cohorts, while a broader study set aims to get >2,000 patients dosed by mid-2027 ahead of potential Phase 3 starts in early 2028. In addition, CR-002 and CR-003 add differentiated ADC upside, with initial data expected in 2027 and a roughly ~$200M EV framework that suggests attractive risk-reward versus the current opportunity set.

Crescent Biopharma is a high-risk, precommercial oncology story whose valuation depends on multiple unproven assets, with DCF assumptions already assigning only 30%/20% approval probabilities for CR-001 in NSCLC/SCLC and 20% for CR-002 and CR-003. The core concern is that CR-001 must still demonstrate competitive safety and efficacy in ASCEND against increasingly strong PD-1/L1 × VEGF regimens, while CR-002 and CR-003 each face unresolved therapeutic-window, payload-delivery, and toxicity questions that could cap dosing or delay development. Adding to the downside case, medium-term dilution risk, licensing/execution risk, and the possibility that early China data fail to reproduce globally could leave the company unable to achieve sales estimates or justify its development trajectory.